CRISPR Therapeutics AG (CRSP) financial statements (2020 and earlier)
Company profile
| Business Address |
BAARERSTRASSE 14 ZUG, CH-6300 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 630 | 457 | 240 | 316 | ||
| Cash and cash equivalents | 630 | 457 | 240 | 316 | ||
| Receivables | 0 | 0 | 3 | 4 | ||
| Other undisclosed current assets | 34 | 10 | 5 | 1 | ||
| Total current assets: | 664 | 466 | 248 | 320 | ||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 31 | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 21 | 19 | 19 | 21 | ||
| Intangible assets, net (including goodwill) | 0 | 0 | 0 | 0 | ||
| Intangible assets, net (excluding goodwill) | 0 | 0 | 0 | 0 | ||
| Restricted cash and investments | 4 | 3 | 3 | 3 | ||
| Other noncurrent assets | 1 | 1 | 1 | 0 | ||
| Total noncurrent assets: | 57 | 23 | 23 | 25 | ||
| TOTAL ASSETS: | 721 | 489 | 271 | 345 | ||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 27 | 26 | 13 | 21 | ||
| Accounts payable | 3 | 5 | 2 | 5 | ||
| Accrued liabilities | 22 | 21 | 11 | 16 | ||
| Taxes payable | 1 | 0 | 0 | 0 | ||
| Deferred revenue | 48 | ✕ | ✕ | ✕ | ||
| Debt | 5 | |||||
| Deferred rent credit | 1 | ✕ | ✕ | |||
| Deferred revenue and credits | ✕ | ✕ | 1 | 1 | ||
| Other liabilities | 0 | 0 | 0 | |||
| Total current liabilities: | 80 | 28 | 15 | 22 | ||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 37 | |||||
| Operating lease, liability | 37 | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 12 | 69 | 69 | 90 | ||
| Deferred revenue and credits | ✕ | ✕ | 69 | 90 | ||
| Deferred revenue | 12 | ✕ | ✕ | ✕ | ||
| Contract with customer, liability | ✕ | 58 | ✕ | ✕ | ||
| Deferred rent credit | 11 | ✕ | ✕ | |||
| Other liabilities | 0 | 0 | 0 | 0 | ||
| Total noncurrent liabilities: | 49 | 69 | 69 | 90 | ||
| Total liabilities: | 129 | 97 | 84 | 112 | ||
| Stockholders' equity | ||||||
| Stockholders' equity attributable to parent | 592 | 392 | 188 | 233 | ||
| Common stock | 2 | 2 | 1 | 1 | ||
| Treasury stock, value | (0) | (0) | ||||
| Additional paid in capital | 846 | 682 | 312 | 289 | ||
| Accumulated other comprehensive income (loss) | (0) | (0) | 0 | (0) | ||
| Accumulated deficit | (255) | (292) | (125) | (57) | ||
| Total stockholders' equity: | 592 | 392 | 188 | 233 | ||
| TOTAL LIABILITIES AND EQUITY: | 721 | 489 | 271 | 345 | ||
Income statement (P&L) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | ||
|---|---|---|---|---|---|
| Revenue, net | ✕ | ✕ | 5 | 1 | |
| Revenue from related parties | 213 | 3 | ✕ | ✕ | |
| Gross profit: | 213 | 3 | 41 | 5 | |
| Operating expenses | (222) | (162) | (106) | (73) | |
| Operating loss: | (9) | (159) | (65) | (68) | |
| Nonoperating income (expense) | (1) | (5) | (2) | 45 | |
| Other nonoperating income (expense) | 5 | (1) | (0) | 79 | |
| Interest and debt expense | 11 | ||||
| Loss from continuing operations before equity method investments, income taxes: | (11) | (164) | (67) | (11) | |
| Loss from equity method investments | (4) | (4) | (2) | (37) | |
| Other undisclosed income from continuing operations before income taxes | 4 | 4 | 2 | 25 | |
| Loss from continuing operations before income taxes: | (11) | (164) | (67) | (23) | |
| Income tax expense | (1) | (1) | (2) | (0) | |
| Net loss: | (11) | (165) | (68) | (23) | |
| Net income attributable to noncontrolling interest | 0 | ||||
| Net loss available to common stockholders, diluted: | (11) | (165) | (68) | (23) | |
Comprehensive Income ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | ||
|---|---|---|---|---|---|
| Net loss: | (11) | (165) | (68) | (23) | |
| Other comprehensive income (loss) | 0 | (0) | 0 | ||
| Other undisclosed comprehensive loss | (0) | ||||
| Comprehensive loss: | (11) | (165) | (68) | (23) | |
| Comprehensive income, net of tax, attributable to noncontrolling interest | 0 | ||||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (0) | (0) | |||
| Comprehensive loss, net of tax, attributable to parent: | (11) | (165) | (68) | (23) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.